Tel-Aviv based AI company Aidoc received FDA clearance for tool that spots strokes on brain CT scans.
Artificial intelligence (AI) start-up company Aidoc, based in Tel-Aviv, has received U.S. Food and Drug Administration clearance for its AI solution that identifies strokes on brain CT scans.
This is Aidoc’s fourth FDA-cleared AI package.
Using deep learning, this AI tool automatically searches every head CT scan for a large-vessel occlusion before the patient leaves the imaging suite. When used in combination with Aidoc’s previously-cleared AI module that flags and prioritizes intracranial hemorrhage, it can identify and triage both ischemic and hemorrhagic stroke in CTs, reducing time-to-treatment, according to a company press release.
“Aidoc’s comprehensive stroke package flags both large vessel occlusion and hemorrhages inside our existing workflows, ensuring we diagnose stroke faster and decide on the best course of treatment,” said Marcel Maya, M.D., co-chair of the department of imaging at Cedars-Sinai Medical Center in the press release.
Once the AI solution identifies a suspected stroke, it immediately pushes the case to the top of the radiologist’s worklist. This step is critical because hemorrhage must be ruled-out before doctors can administer a thrombolytic agent used in thrombolysis or mechanical thrombectomy.
The AI package has already made a positive impact on Cedars-Sinai department, as well on the patients’ length of stay in the hospital, Maya said. And, according to company information, additional research conducted at the University of Rochester Medical Center, and confirmed by Yale-New Haven Hospital, revealed this tool can reduce turnaround time for emergency room patients with intracranial hemorrhage by 36.6 percent.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.